LONDON--(BUSINESS WIRE)--Sep 8, 2026--
Today, Globality launches Glo 2.0, an enterprise platform for autonomous sourcing that streamlines the entire intake-to-award process.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908880093/en/
Analysis shows that over half of all addressable enterprise spend is still not competitively sourced. Capacity limits force procurement teams to focus only on their highest-stakes events and leave the rest untouched, a tradeoff that costs businesses millions. Glo 2.0 removes that constraint: AI agents work as an extension of the procurement team, running entire sourcing events so teams can clear their backlogs.
Glo 2.0 is a single platform for procurement teams, with specialized AI agents that act as an extension of your team and run entire sourcing events, including negotiating with suppliers. Teams can choose to let AI run sourcing events fully autonomously or operate in collaborative mode with team members “in the loop” where specified.
AI That Reasons, Acts, and Negotiates Autonomously
Globality has long been the dedicated leader in agentic sourcing. Glo 2.0 is the next wave of that innovation with agents that reason, act, and make decisions on their own.
For years, AI in sourcing was limited to the early stages of an event; drafting an RFx and flagging relevant suppliers before handing off to a person. Procurement managers still had to run the actual event, and each could realistically manage only a handful at a time. This forced teams to prioritize which events to pursue.
Now, AI can run the entire sourcing event, from intake-to-award. It generates the RFx, finds and invites suppliers, negotiates, and analyzes the results, without a person managing each step. Trained on current negotiation techniques, Glo 2.0 handles supplier negotiations autonomously and simultaneously on the terms that matter, including price, quality, delivery, service, and risk. After the negotiation, Glo conducts scenario analysis and recommends the best supplier and scenario.
"This is the first truly autonomous sourcing platform where AI runs the complete intake-to-award process. Our agents don’t just automate a workflow; they reason through the data, decide the right approach for what’s being sourced, and act on your behalf with suppliers."
— Joel Hyatt, Co-Founder and CEO, Globality
“Globality’s autonomous sourcing represents a meaningful opportunity to scale our sourcing work, enabling us to run more events efficiently and ultimately deliver greater value.”
— Samer Ijaz, Head of Strategic Sourcing, Dropbox
Autonomy, on Your Terms
Every sourcing event carries its own risk, value, and governance requirements, so Glo 2.0 lets teams decide how much of each event to hand over. Autonomy levels can be set organization-wide, by category, or for a single event.
In Collaborative Mode, Glo 2.0 works with the team: the team leads supplier interactions and makes the award decision, while the platform delivers the commercial reasoning, builds the RFx, and sets negotiation strategy. In Autonomous Mode, Glo 2.0 works for the team: procurement defines the objectives, sets the guardrails, and approves the final award, while the platform runs everything in between. No other solution offers both options.
Glo Intake: The Intelligent Front Door for Employee Purchasing
Sourcing opportunities are often lost before they begin, buried in disconnected, rules-based legacy systems that require extensive training and inadvertently misallocate spend. Business stakeholders want to purchase a good or service, not learn a purchasing process. Complicated tools and outdated forms leave users unsure which system to use or what the procurement rules are.
Glo Intake replaces this with a single conversational front door. It interprets what the stakeholder is asking for, applies the organization’s procurement policies, and routes the request to the right path, no training or system-hopping required.
The platform runs a should-cost analysis to measure the gap between what has been submitted and what the market supports, giving procurement the clarity to identify which purchases are worth competitively sourcing before any supplier commitment is made.
Your Best Event, Every Time
Most teams reserve their deepest commercial rigor for their largest events. With Glo 2.0, every event in the portfolio — strategic indirect, tail, and direct spend alike — gets the same depth as the best event the team has ever run. Categories once too small or time-consuming to source competitively now receive full competitive treatment. Every event carries a full audit trail with AI explainability, enforces policy and guardrails automatically, and runs on a platform certified to SOC 2 and ISO 27001.
Clear the Backlog, Capture the Savings
An event that typically takes six to ten weeks now closes in days. Customers report running five to nine times more sourcing events without adding headcount, and Global 2000 companies have achieved annual cost savings of 10 to 20 percent.
Early customers are already seeing the impact:
"We’ve been impressed by what Globality has delivered for our procurement organization over the years, and the early results from autonomous mode are the most exciting yet. We’re competitively sourcing spend we simply didn’t have the capacity to reach before."
— Steve Dyson, VP of Global Indirect Procurement, HP
Packaging, Availability and Resources
Glo 2.0 is available immediately as an upgrade to Glo.
Register for the Glo 2.0 launch webinar here.
About Globality
Globality is the autonomous sourcing platform that manages the complete intake-to-award process.
We deliver 60–90% faster cycle times, 10–20% annual cost savings, and bottom-line impact for leading enterprises including BT, Tesco, Swiss Re, Fidelity, Societe Generale, UPS, and HP.
For more information, visit Globality.com.
Procurement LIVE: The London Summit
September 8-9, 2026
QEII Centre
Booth #H3
Glo 2.0 - Negotiation
ATHLONE, Ireland--(BUSINESS WIRE)--Sep 8, 2026--
Dunbar Pharmaceuticals(“Dunbar Pharma” or “the Company”), Ireland's first EU GMP-certified manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs), today announced that it will attend expopharm 2026 in Munich from 15–17 September 2026 at Messe München, Am Messesee 2, 81829 Munich, Germany. expopharm, a leading European trade fair serving the pharmacy market, brings together pharmacists, pharmaceutical companies and other industry stakeholders from across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908267524/en/
Dunbar Pharma’s discussions at expopharm will focus on its presentation, “Quality Beyond the Certificate - What Makes a Reliable Dronabinol API?” The company will discuss why a certificate of analysis (CoA) alone does not provide a complete assessment of API quality, and how standardised pharmaceutical manufacturing, batch-to-batch consistency and reliable long-term supply help pharmacists prepare compounded medicines consistently and support continuity of patient care.
Dunbar Pharma markets its plant-derived dronabinol API under the trademark WaterClear THC™.
Founder and CEO Leah Fletcher and members of the Dunbar Pharma team will be available at Hall A2, Stand A43, to meet with pharmacists, pharmaceutical partners and other industry stakeholders.
Dunbar Pharma will also participate in expopharm’s medical cannabis guided tour, held daily from 12:20 to 13:20. During the tour, Melanie Dolfen, a pharmacist specialising in medical cannabis and owner of BezirksApotheke Berlin, will join Dunbar to discuss how pharmacists assess API quality and share her experience using Dunbar Pharma’s dronabinol in pharmacy compounding.
“expopharm is an important opportunity for us to meet directly with compounding pharmacists and discuss how pharmaceutical-grade, plant-derived dronabinol can support their work and their patients," said Leah Fletcher, Founder and CEO of Dunbar Pharma. “We manufacture and supply WaterClear THC™ at commercial scale in Ireland under EU GMP, providing pharmacists with the quality, consistency and reliable supply they require. Having established our product in Germany and expanded into the UK, we look forward to building new pharmacy relationships in Munich and supporting broader access to dronabinol-based medicines.”
Dunbar Pharma’s presence at expopharm follows the Company’s commercial launch and supply of its plant-derived dronabinol API in Germany, one of Europe’s most established dronabinol markets, and its subsequent entry into the UK through an agreement with IPS Pharma. The agreement makes WaterClear THC™ available through the UK’s regulated Specials framework, enabling clinicians to source pharmaceutical-grade, plant-derived dronabinol through IPS Pharma’s established supply network.
Dunbar Pharma manufactures WaterClear THC™ at commercial scale at its EU GMP-certified facility in Athlone, Ireland, under the oversight of the Health Products Regulatory Authority (HPRA). The Company’s validated manufacturing process and full batch traceability are designed to provide the consistency and continuity of supply required for regulated pharmaceutical medicines.
WaterClear THC™ is a chemically defined active pharmaceutical ingredient manufactured to recognised pharmacopoeia standards. Unlike botanical cannabis preparations, it enables consistent milligram dosing and has minimal compositional variability, providing pharmaceutical-grade precision for individualised prescribing. While dronabinol has historically been produced synthetically, Dunbar Pharma uses a proprietary process based on plant-derived starting materials.
To arrange a meeting with Dunbar Pharma at expopharm, contact pr@dunbarpharma.ie. Attendees can visit the Company in Hall A2, Stand A43.
About Dunbar Pharmaceuticals
Dunbar Pharmaceuticals (Mercury Rising Ltd.) is a privately owned Irish pharmaceutical manufacturer and Ireland's first EU GMP manufacturer of plant-derived cannabinoid active pharmaceutical ingredients (APIs). Based in Athlone, Ireland, the company manufactures difficult-to-make, pharmaceutical-grade APIs, including plant-derived dronabinol, to recognised pharmacopoeia standards for regulated pharmaceutical markets, including Germany and the UK.
Built from the ground up as a pharmaceutical manufacturer on Ireland's world-class pharma platform, Dunbar Pharma operates under the oversight of the Health Products Regulatory Authority (HPRA), with validated processes and full batch traceability supporting dependable supply to licensed partners across Europe.
Dunbar Pharma was founded on a simple observation: medical use of cannabinoids was growing worldwide, but the pharmaceutical infrastructure behind it had not kept pace. The company is closing that gap, building Europe's pharmaceutical infrastructure for plant-derived cannabinoid medicines by combining EU GMP manufacturing, pharmaceutical quality standards and reliable supply for healthcare partners and patients. The company has been recognised for its growth and innovation, including Emerging Company of the Year at the BioPharmaChem Impact Awards 2026, Product & Manufacturing Start-Up of the Year at the National Start-Up Awards 2025, and the Ambition & Growth Award at the Local Enterprise Office Awards 2026. Keep up to date on activity from Dunbar Pharma on LinkedIn.
Notes to Editor
Dunbar Pharmaceuticals (Mercury Rising Ltd.) is an Irish GMP manufacturer based in Athlone, Ireland. GMP Certificate: 35486/ASR13213/000001; ASR Certificate: ASR13213/000001 — verifiable on the EudraGMDP public register.
Dronabinol is the INN (international non-proprietary name) for delta-9-THC in purified pharmaceutical form, prescribed internationally for decades in regulated prescription medicines for specific indications.
In the UK, “Specials” are unlicensed medicines manufactured or supplied to meet the individual clinical needs of a specific patient where no suitable licensed alternative is available. They are prescribed by clinicians and produced by licensed Specials manufacturers, such as IPS Pharma, under MHRA oversight.
Dunbar's dronabinol is manufactured exclusively for pharmaceutical use, not consumer or wellness products.
.
Dunbar Pharma to Showcase European Dronabinol Supply Capabilities at expopharm 2026 in Munich
